Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Silica is a proven and highly effective anti-caking agent that has been used for decades
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
The company will also share results in two additional posters for deuruxolitinib
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
These accolades highlight our unwavering commitment to maintaining the highest safety standards
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
Subscribe To Our Newsletter & Stay Updated
